Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602632 | 0.89 | SCD5 (0.51) | RPS6KA2KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL3603305 | 0.88 | F2 (0.47) | RPS6KA2ALDH1A1KMT2AWNT1GSK3B | |
| SCHEMBL13504884 | 0.87 | NAMPT (0.60) | RPS6KA2ALDH1A1NAMPT | |
| Hydrochloric Acid SCHEMBL3609045 | 0.87 | F2 (0.46) | RPS6KA2ALDH1A1KMT2AWNT1GSK3B | |
| SCHEMBL13504959 | 0.87 | SCD5 (0.52) | RPS6KA2CYP2C19WNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL3606790 | 0.86 | SCD5 (0.51) | RPS6KA2CYP2C19WNT1GSK3BDYRK1A | |
| Hydrochloric Acid SCHEMBL3612494 | 0.86 | NAMPT (0.59) | RPS6KA2ALDH1A1NAMPT | |
| SCHEMBL3606398 | 0.85 | SMN1; SMN2 (0.52) | RPS6KA2SMN1; SMN2ALDH1A1POLBMEN1 | |
| SCHEMBL3608690 | 0.85 | TAS2R8 (0.52) | RPS6KA2SMN1; SMN2ALDH1A1WNT1GSK3B | |
| SCHEMBL3608032 | 0.83 | MEN1 (0.55) | KDM4ESMN1; SMN2HPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | claimed |
| EP-2144895-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2010-01-20 | — | — | EP | claimed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | claimed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| EP-2144895-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SmithKline Beecham Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | RPS6KA2 2661/4885KDM4E 1083/4885RAB9A 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.